A: Counts of CECs, CD109+ CECs, CD45dimCD34+VEGFR2+ hp, CD140b+ PPCs before therapy and 2 months after treatment onset in patients responding to treatment with bevacizumab and irinotecan. B: Counts of CECs, CD109+ CECs, CD45dimCD34+VEGFR2+ hp, CD140b+ PPCs before therapy and 2 months after treatment onset in patients responding to treatment with bevacizumab alone (IDA).
Boxes: the interquartile range; lines: location of first quartile, median, and third quartile. ○, outliers beyond the standard span. All P values were calculated by Wilcoxon test. Abbreviations: CECs, circulating endothelial cells; hp, hematopoietic progenitor cells; PPCs, progenitor perivascular cells; VEGFR, vascular endothelial growth factor receptor.